Glial cells

DEA Gives Colorado’s MedPharm the Green Light for Schedule 1 Research License

Retrieved on: 
Thursday, July 15, 2021
Alternative medicine, Public policy, Government, Health, Other Policy Issues, Research, Science, Pharmaceutical, Glial cells, Drug Enforcement Administration, Glia, Microglia, Government, Drug policy, Federal government of the United States

MedPharm Research, a wholly owned subsidiary of MedPharm Holdings, a leading medical cannabis manufacturer, R&D laboratory, and compounding facility, announces that they have been approved for a Drug Enforcement Administration (DEA) Schedule I Researcher License.

Key Points: 
  • MedPharm Research, a wholly owned subsidiary of MedPharm Holdings, a leading medical cannabis manufacturer, R&D laboratory, and compounding facility, announces that they have been approved for a Drug Enforcement Administration (DEA) Schedule I Researcher License.
  • The DEA makes the final determination on approving applications for research using schedule I substances and drugs.
  • Its been a long road to getting a federally approved license, Albert Gutierrez, CEO of MedPharm Research, says.
  • The DEA license enables MedPharm Research to isolate and evaluate the activity of phytocannabinoids on different brain cells (such as neuron, astrocytes, microglia).

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Tyrosine kinases, Multiple sclerosis, Life sciences, Bruton's tyrosine kinase, Biology, Glial cells, Tyrosine kinase, Multiple sclerosis research, Microglia, Biogen, Protein kinase inhibitor

For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.

Key Points: 
  • For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.
  • BTK inhibitors may have the potential to transform the treatment paradigm of autoimmune diseases, in particular MS.
  • Orelabrutinib is a small molecule Brutons tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases.
  • Among myeloid cells expressing BTK, microglia, which reside in the CNS, have been shown to express high level of BTK in multiple sclerosis.

Neuraly Announces Publication in Acta Neuropathologica Communications of Preclinical Data Detailing the Neuroprotective Effect of NLY01 in Models of Alzheimer’s Disease

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Branches of biology, Glial cells, Microglia, Astrocyte, Alpha-synuclein, Neurodegeneration, Amyloid plaques, Glia, NLY01, Neuraly, NLY01, NEURALY

\xe2\x80\x9cTo date, we have shown that NLY01 can reduce \xce\xb2-amyloid plaque burden in mouse models of Alzheimer\xe2\x80\x99s and abnormal alpha-synuclein build up in Parkinson\xe2\x80\x99s models.

Key Points: 
  • \xe2\x80\x9cTo date, we have shown that NLY01 can reduce \xce\xb2-amyloid plaque burden in mouse models of Alzheimer\xe2\x80\x99s and abnormal alpha-synuclein build up in Parkinson\xe2\x80\x99s models.
  • \xe2\x80\x9cDuring progression, resident microglia undergo proinflammatory activation, resulting in an increased capacity to convert resting astrocytes to reactive astrocytes.
  • NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R) is highly expressed on glial cells.
  • NLY01 is being developed as a disease-modifying agent for neurodegenerative disorders including Parkinson\xe2\x80\x99s and Alzheimer\xe2\x80\x99s disease.

New Research Study Investigates Metformin as a Therapy to Promote Brain Repair and Reduce Disability in Children and Young Adults with MS

Retrieved on: 
Tuesday, February 2, 2021
Branches of biology, Drugs, Glial cells, Myelin, Oligodendrocyte, Metformin, Health sciences, Preclinical development

These partnerships are critical for leveraging more research dollars and increased impact for the benefit of Canadian health.

Key Points: 
  • These partnerships are critical for leveraging more research dollars and increased impact for the benefit of Canadian health.
  • Preclinical evidence shows metformin enhances oligodendrocytes cells that produce myelin and promotes white matter repair in animal models and in youth with radiation-induced brain injury.
  • This research aims to translate these preclinical findings from animal and human studies into clinical practice by conducting a pilot feasibility trial.
  • This strategic funding valued at $118M has benefitted approximately 196 world-class research groups and 3,300 trainees and has catalyzed24clinical trials.

Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury

Retrieved on: 
Tuesday, December 8, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Branches of biology, Biology, Stem cells, Glial cells, Life sciences, Biotechnology, Biology of bipolar disorder, Oligodendrocyte, Lineage Cell Therapeutics, Stem-cell therapy, Spinal Cord Injuries, OPC1, the OPC1 Clinical Study, Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1 , its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1 , its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI).
  • The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with acute spinal cord injuries (SCI).
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases

Retrieved on: 
Tuesday, December 8, 2020
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Glial cells, Macrophages, Microglia

Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing.

Key Points: 
  • Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing.
  • Atlas Venture co-founded, seeded and incubated Vigil with late pre-clinical-stage assets in-licensed from Amgen Inc., who will remain a key shareholder in the company.
  • The Series A round was co-led by Atlas Venture and Northpond Ventures and includes participating investors Hatteras Venture Partners and Alexandria Venture Investments.
  • We have identified multiple neurodegenerative diseases with clear evidence of genetically linked microglial dysfunction impacting small and large patient populations.

Glia and LitLingo Announce Strategic Partnership to Enhance Compliance Monitoring with Artificial Intelligence for Financial Services

Retrieved on: 
Tuesday, December 1, 2020
Professional services, Data management, Security, Technology, Software, Finance, Banking, Glial cells, Glia, LitLingo, Glia

LitLingo Technologies , an AI company providing proactive compliance and risk-mitigation technology and Glia , a leading provider of Digital Customer Service, are partnering to offer AI-driven compliance functionality to Glia customers.

Key Points: 
  • LitLingo Technologies , an AI company providing proactive compliance and risk-mitigation technology and Glia , a leading provider of Digital Customer Service, are partnering to offer AI-driven compliance functionality to Glia customers.
  • With the LitLingo offering, agents using Glia have access to real-time corrective alerts to create a better, more consistent experience for end-customers and reduced compliance risk for financial institutions .
  • By leveraging LitLingos proprietary AI, Glia customers can reduce human error during interactions with customers and gain insights into compliance and NPS problem areas.
  • Glia customers now have access to LitLingo's monitoring software that uses natural language understanding to comprehend complex language and identify specific concepts.

Sana Biotechnology Announces Acquisition of Oscine

Retrieved on: 
Friday, October 30, 2020
Branches of biology, Biology, Life sciences, Glial cells, Stem cells, Cloning, Developmental biology, Glia, Biotechnology, Progenitor cell, Draft:Steven Goldman

SEATTLE, Oct. 30, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition ofOscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS).

Key Points: 
  • SEATTLE, Oct. 30, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition ofOscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS).
  • "We are excited about the potential of the glial progenitor cell program Oscine has been developing to help patients with a number of different diseases of the brain.
  • Steve Goldman, M.D., Ph.D.,was Oscine's scientific founder and joins Sana as the Head of CNS Therapy.Dr.
  • Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients.

Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell™ Universal Donor Stem Cell Therapy for Brain Injury

Retrieved on: 
Monday, September 28, 2020
Branches of biology, Biology, Life sciences, Glial cells, Stem cells, Biotechnology, Developmental biology, Developmental neuroscience, Glia, Microglia, Dentate gyrus, Adult stem cell

OCEANSIDE, Calif., Sept. 28, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI), reported today positive preclinical data demonstrating superior neuro-regenerative activity to other cell therapies such as mesenchymal stem cells.

Key Points: 
  • OCEANSIDE, Calif., Sept. 28, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI), reported today positive preclinical data demonstrating superior neuro-regenerative activity to other cell therapies such as mesenchymal stem cells.
  • Using animal models, Company collaborators demonstrated stimulation of stem cell proliferation that reside in parts of the brain called the "dentate gyrus".
  • Additionally, the Company reported protection of neurons from inflammation associated cell death as well as reduction of inflammatory proteins produced by brain cells called "microglia".
  • "Brain injury in the form of Chronic Traumatic Encephalopathy is a major scourge on the bravest elements of our society: the veterans.

AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference

Retrieved on: 
Monday, September 14, 2020
Branches of biology, Medical specialties, Immune system, Medicine, Multiple sclerosis, Glial cells, Masitinib, Microglia, T cell, Macrophage, Innate immune system, Multiple sclerosis research

"To date, there is no treatment capable of effectively targeting the cells that play a major role in the evolution of the progressive forms of multiple sclerosis.

Key Points: 
  • "To date, there is no treatment capable of effectively targeting the cells that play a major role in the evolution of the progressive forms of multiple sclerosis.
  • In progressive multiple sclerosis, innate3 immune cells such as macrophages, microglia or mast cells have been shown to probably play a major role.
  • AB Science's lead product, masitinib, is an oral tyrosine kinase inhibitor that specifically targets the innate immunity of patients with multiple sclerosis.
  • "With this conclusive study, AB Science is now on the verge of becoming the first biotech company in the world to propose a new approach for the treatment of progressive forms of multiple sclerosis.